QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
NASDAQ:IMNN

Imunon (IMNN) Stock Price, News & Analysis

$1.14
+0.02 (+1.33%)
(As of 10:37 AM ET)
Today's Range
$1.09
$1.16
50-Day Range
$0.49
$1.93
52-Week Range
$0.48
$2.00
Volume
24,614 shs
Average Volume
191,078 shs
Market Capitalization
$10.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Imunon MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,055.6% Upside
$13.00 Price Target
Short Interest
Healthy
4.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Imunon in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.27) to ($1.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.69 out of 5 stars

Medical Sector

566th out of 918 stocks

Pharmaceutical Preparations Industry

263rd out of 430 stocks

IMNN stock logo

About Imunon Stock (NASDAQ:IMNN)

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

IMNN Stock Price History

IMNN Stock News Headlines

New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Imunon, Inc. (IMNN) Q4 2023 Earnings Call Transcript
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Imunon, Inc.: IMUNON Announces Leadership Change
IMUNON CEO steps down, Executive Chairman takes helm
IMUNON Announces Leadership Change
IMUNON reports promising vaccine study results
Bicycle Therapeutics Ltd. ADR
See More Headlines
Receive IMNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMNN
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$13.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+1,055.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-19,510,000.00
Pretax Margin
-23,541.60%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$1.42 per share

Miscellaneous

Free Float
9,039,000
Market Cap
$10.58 million
Optionable
Not Optionable
Beta
2.03
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael H. Tardugno (Age 73)
    Executive Chairman
    Comp: $1.58M
  • Mr. Jeffrey W. Church CPA (Age 67)
    CFO, Executive VP & Corporate Secretary
    Comp: $548.92k
  • Dr. Khursheed Anwer M.B.A. (Age 64)
    Ph.D., Executive VP & Chief Scientific Officer
    Comp: $540.87k
  • Mr. Timothy J. Tumminello CPA (Age 66)
    Chief Accounting Officer & Controller
    Comp: $108.31k
  • Ms. Marianne M. Lambertson
    Vice President of Communications & Investor Relations
  • Dr. Sebastien Hazard M.D. (Age 52)
    Executive VP & Chief Medical Officer

IMNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Imunon stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Imunon in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNN shares.
View IMNN analyst ratings
or view top-rated stocks.

What is Imunon's stock price target for 2024?

1 equities research analysts have issued 12-month price targets for Imunon's stock. Their IMNN share price targets range from $13.00 to $13.00. On average, they expect the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 1,055.6% from the stock's current price.
View analysts price targets for IMNN
or view top-rated stocks among Wall Street analysts.

How have IMNN shares performed in 2024?

Imunon's stock was trading at $0.68 on January 1st, 2024. Since then, IMNN shares have increased by 65.4% and is now trading at $1.1250.
View the best growth stocks for 2024 here
.

When is Imunon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IMNN earnings forecast
.

How do I buy shares of Imunon?

Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMNN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners